AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34741530 — intervention group
Group type: COMPARATOR
Intervention: FLO alone (control)
Number of subjects: 78
Study 33861704 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-trial training
Number of subjects: 16
Study 33861704 — intervention group
Group type: COMPARATOR
Intervention: One-trial training
Number of subjects: 16
Study 32654400 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard single pass (SP) emission with 755 alexandrite laser
Number of subjects: 108
Study 32654400 — intervention group
Group type: COMPARATOR
Intervention: Multipass emission (Moveo handpiece) with 755 alexandrite laser
Number of subjects: 108
Study 32654400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 108
Study 35119183 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4796
Study 35119183 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4796
Study 34984068 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step Resilience-Oriented Intervention (TROI)
Number of subjects: 70
Study 34984068 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 70
Study 34057133 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument‐assisted manual (IM) technique
Number of subjects: 39
Study 34057133 — intervention group
Group type: COMPARATOR
Intervention: Conventional static stretching (SS) technique
Number of subjects: 39
Study 34057133 — intervention group
Group type: COMPARATOR
Intervention: Hold-relax (HR) manual technique
Number of subjects: 39
Study 34664845 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-demand oxygen delivery system (auto-DODS)
Number of subjects: 8
Study 34664845 — intervention group
Group type: COMPARATOR
Intervention: Conventional demand oxygen delivery system (conventional DODS)
Number of subjects: 8
Study 32467558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral catheter use during arteriovenous fistula
Number of subjects: 50
Study 32467558 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ureteral catheter)
Number of subjects: 50
Study 36255564 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 106
Study 36255564 — intervention group
Group type: COMPARATOR
Intervention: endoscopic + β‐blocker
Number of subjects: 106
Study 35978446 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (Prozac) for 9 months
Number of subjects: 100
Study 35978446 — intervention group
Group type: COMPARATOR
Intervention: Calcium for 9 months
Number of subjects: 100
Study 33394328 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 79
Study 33394328 — intervention group
Group type: EXPERIMENTAL
Intervention: MAD
Number of subjects: 79
Study 36087104 — intervention group
Group type: EXPERIMENTAL
Intervention: FODMAPs
Number of subjects: 0
Study 36087104 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten
Number of subjects: 0
Study 36087104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32965653 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular follow-up and supportive interventions
Number of subjects: 38
Study 32965653 — intervention group
Group type: COMPARATOR
Intervention: Children with idiopathic nephrotic syndrome
Number of subjects: 38
Study 32267727 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate‐ to high‐intensity physical activity (PA)
Number of subjects: 31
Study 32267727 — intervention group
Group type: COMPARATOR
Intervention: Control day without PA
Number of subjects: 31
Study 33351458 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS (Enhanced Recovery After Surgery)
Number of subjects: 64
Study 33351458 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 64
Study 34076375 — intervention group
Group type: EXPERIMENTAL
Intervention: subgingival application of injectable platelet-rich fibrin (i-PRF)
Number of subjects: 15
Study 34076375 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 15
Study 34732271 — intervention group
Group type: EXPERIMENTAL
Intervention: Educative article featuring a person mastering a suicidal crisis
Number of subjects: 172
Study 34732271 — intervention group
Group type: COMPARATOR
Intervention: Unrelated article (Control)
Number of subjects: 172
Study 32936598 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly cycling sprints (4 s × 5 per hour × 8 h = 160 s·d SPRINTS)
Number of subjects: 8
Study 32936598 — intervention group
Group type: COMPARATOR
Intervention: 8-h period of sitting (SIT)
Number of subjects: 8
Study 34008525 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification‐goniosynechialysis (phaco‐GSL)
Number of subjects: 79
Study 34008525 — intervention group
Group type: COMPARATOR
Intervention: Phacotrabeculectomy
Number of subjects: 79
Study 34180118 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium concentration (HNa, 143 mEq/L)
Number of subjects: 19
Study 34180118 — intervention group
Group type: COMPARATOR
Intervention: Low sodium concentration (LNa, 138 mEq/L)
Number of subjects: 19
Study 34260424 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour repositioning interval using an air mattress
Number of subjects: 251
Study 34260424 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour repositioning interval using a foam mattress
Number of subjects: 251
Study 34260424 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour repositioning interval using a foam mattress
Number of subjects: 251
Study 35788995 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 35788995 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32020028 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg once daily)
Number of subjects: 50
Study 32020028 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 50
Study 35920763 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (RZB) 150 mg
Number of subjects: 0
Study 35920763 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study 32854477 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 and PD-L1 high expression in EOC tissues
Number of subjects: 180
Study 32854477 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 high expression in serous carcinoma
Number of subjects: 180
Study 32854477 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 high expression in serous carcinoma
Number of subjects: 180
Study 32854477 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 and PD-L1 high expression in early vs late stage EOC
Number of subjects: 180
Study 32854477 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 and PD-L1 expression in high-grade vs low-grade EOC
Number of subjects: 180
Study 32854477 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival analysis based on PD-1 and PD-L1 expression
Number of subjects: 180
Study 36455284 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced injection technique (5 injection sites)
Number of subjects: 77
Study 36455284 — intervention group
Group type: COMPARATOR
Intervention: Standard injection technique (20 injection sites)
Number of subjects: 77
Study 34455912 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 91
Study 34455912 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 91
Study 34455912 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 91
Study 32321288 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency stimulation of the sphenopalatine ganglion for 30 min
Number of subjects: 12
Study 32321288 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation for 30 min
Number of subjects: 12
Study 32321288 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency stimulation
Number of subjects: 12
Study 34995276 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 800
Study 34995276 — intervention group
Group type: COMPARATOR
Intervention: Angiogram-guided PCI
Number of subjects: 800
Study 33230924 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad pre-eclampsia definition (proteinuria or one/more maternal symptoms, signs or abnormal laboratory tests)
Number of subjects: 987
Study 33230924 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive pre-eclampsia definition (new proteinuria)
Number of subjects: 987
Study 33230924 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad pre-eclampsia definition with addition of fetoplacental manifestations (stillbirth or birthweight <10th centile)
Number of subjects: 987
Study 33230924 — intervention group
Group type: EXPERIMENTAL
Intervention: Main CHIPS trial outcomes
Number of subjects: 987
Study 32822637 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation with a multiple independent constant current‐controlled device
Number of subjects: 0
Study 32822637 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 35361008 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 200
Study 35361008 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study 33314880 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity with blood flow restriction (LI-BFR; N=10; trained at 30-40% of VO2 reserve with BFR)
Number of subjects: 39
Study 33314880 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group (N=10)
Number of subjects: 39
Study 32865374 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg daily
Number of subjects: 984
Study 32865374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study 35077557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 221
Study 35077557 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 221
Study 33744591 — intervention group
Group type: EXPERIMENTAL
Intervention: Matcha (2 g daily for 2 weeks)
Number of subjects: 42
Study 33744591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 32614625 — intervention group
Group type: EXPERIMENTAL
Intervention: Respimat
Number of subjects: 180
Study 32614625 — intervention group
Group type: EXPERIMENTAL
Intervention: pMDI
Number of subjects: 180
Study 32614625 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskhaler
Number of subjects: 180
Study 32614625 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskus
Number of subjects: 180
Study 32614625 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerolizer
Number of subjects: 180
Study 32614625 — intervention group
Group type: EXPERIMENTAL
Intervention: Handihaler
Number of subjects: 180
Study 32614625 — intervention group
Group type: EXPERIMENTAL
Intervention: Easyhaler
Number of subjects: 180
Study 32614625 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbohaler
Number of subjects: 180
Study 32614625 — intervention group
Group type: EXPERIMENTAL
Intervention: Breezhaler
Number of subjects: 180
Study 32614625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellipta
Number of subjects: 180
Study 35896167 — intervention group
Group type: EXPERIMENTAL
Intervention: Covexir® (F. foetida oleo-gum)
Number of subjects: 0
Study 33359791 — intervention group
Group type: EXPERIMENTAL
Intervention: mAb AR9.6
Number of subjects: 0
Study 33359791 — intervention group
Group type: EXPERIMENTAL
Intervention: mAb AR9.6 alone or in combination with gemcitabine
Number of subjects: 0
Study 34297496 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg abelacimab
Number of subjects: 412
Study 34297496 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg abelacimab
Number of subjects: 412
Study 34297496 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg abelacimab
Number of subjects: 412
Study 34297496 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (40 mg)
Number of subjects: 412
Study 33227220 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT (60 J; 1152 mW; 52 sec; and 166.75 cm2) applied on biceps brachii
Number of subjects: 30
Study 33227220 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 35000898 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) treatment
Number of subjects: 303
Study 35000898 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) treatment
Number of subjects: 303
Study 33984185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-dominant moisturizing cream and cleanser
Number of subjects: 0
Study 33984185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34088244 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital storytelling video
Number of subjects: 247
Study 34088244 — intervention group
Group type: COMPARATOR
Intervention: Brochure
Number of subjects: 247
Study 33629973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent palm cooling during exercise (PCex)
Number of subjects: 34
Study 33629973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent palm cooling during and post-exercise (PCex&post)
Number of subjects: 34
Study 33629973 — intervention group
Group type: COMPARATOR
Intervention: No palm cooling (NoPC)
Number of subjects: 34
Study 35642832 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen administration
Number of subjects: 71
Study 35642832 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 32242806 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab treatment
Number of subjects: 91
Study 32242806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 35150788 — intervention group
Group type: EXPERIMENTAL
Intervention: HF1 (39 Gy in 13 fractions)
Number of subjects: 253
Study 35150788 — intervention group
Group type: EXPERIMENTAL
Intervention: HF2 (45 Gy in 15 fractions)
Number of subjects: 253
Study 35150788 — intervention group
Group type: COMPARATOR
Intervention: CF (54 Gy in 30 fractions)
Number of subjects: 253
Study 35150788 — intervention group
Group type: EXPERIMENTAL
Intervention: HF1
Number of subjects: 253
Study 35150788 — intervention group
Group type: EXPERIMENTAL
Intervention: HF2
Number of subjects: 253
Study 35150788 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients (2-5 years)
Number of subjects: 253
Study 32164767 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin (80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min)
Number of subjects: 15
Study 32164767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 34355605 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill rehabilitation
Number of subjects: 73
Study 34355605 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (control)
Number of subjects: 73
Study 34130035 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic hypothermia (33–35 °C)
Number of subjects: 40
Study 34130035 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (37 °C)
Number of subjects: 40
Study 34866567 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted CBT (BIACA)
Number of subjects: 202
Study 34866567 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-practice CBT (CC)
Number of subjects: 202
Study 33222296 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-implants (4-I)
Number of subjects: 56
Study 33222296 — intervention group
Group type: COMPARATOR
Intervention: 6-implants (6-I)
Number of subjects: 56
Study 36354206 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (1.0-1.5 MAC)
Number of subjects: 289
Study 36354206 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based total intravenous anesthesia (2.0-3.0 mg/kg/h)
Number of subjects: 289
Study 36354206 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 289
Study 36354206 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based total intravenous anesthesia
Number of subjects: 289
Study 33877728 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg/day for 12 weeks
Number of subjects: 32
Study 33877728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 32513881 — intervention group
Group type: EXPERIMENTAL
Intervention: For Our Children's Sake (FOCS) intervention, group format over 10 weeks
Number of subjects: 76
Study 35353909 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry induction
Number of subjects: 90
Study 35353909 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry reduction
Number of subjects: 90
Study 35353909 — intervention group
Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 90
Study 35353909 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait worry
Number of subjects: 90
Study 35353909 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with internalizing disorders
Number of subjects: 90
Study 34559837 — intervention group
Group type: EXPERIMENTAL
Intervention: MoveStrong program (balance and functional strength training with protein intake focus)
Number of subjects: 44
Study 32333847 — intervention group
Group type: COMPARATOR
Intervention: AVA (Anthrax Vaccine Adsorbed)
Number of subjects: 573
Study 32333847 — intervention group
Group type: EXPERIMENTAL
Intervention: AVA plus raxibacumab
Number of subjects: 573
Study 32333847 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AVA and AVA plus raxibacumab
Number of subjects: 573
Study 32333847 — intervention group
Group type: COMPARATOR
Intervention: Safety population
Number of subjects: 573
Study 35256150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose 1000 mg and darbepoetin 200 μg subcutaneously
Number of subjects: 156
Study 35256150 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulphate 600 mg daily
Number of subjects: 156
Study 34187756 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (HF) transcutaneous auricular vagus nerve stimulation at 25Hz
Number of subjects: 57
Study 34187756 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency (LF) transcutaneous auricular vagus nerve stimulation at 1Hz
Number of subjects: 57
Study 35296793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic parenteral nutrition (IDPN) for 3 months
Number of subjects: 38
Study 35296793 — intervention group
Group type: COMPARATOR
Intervention: Control group received intensive dietary counselling for 3 months
Number of subjects: 38
Study 35103070 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline aerosol inhalation (3% saline)
Number of subjects: 0
Study 34232160 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Pressure Variability (BPv)
Number of subjects: 0
Study 34232160 — intervention group
Group type: COMPARATOR
Intervention: CVD events from long-term posttrial follow-up (ACCORDION)
Number of subjects: 0
Study 35553187 — intervention group
Group type: EXPERIMENTAL
Intervention: ebselen (10 mg/kg i.p.)
Number of subjects: 11
Study 35553187 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 11
Study 32219557 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA 400 U
Number of subjects: 100
Study 32219557 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA 250 U
Number of subjects: 100
Study 32219557 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 35931132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentalong® 50mg (PETN) twice daily
Number of subjects: 317
Study 35931132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 33751203 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block with 20 mL of 0.25% bupivacaine
Number of subjects: 54
Study 33751203 — intervention group
Group type: COMPARATOR
Intervention: Sham block with 20 mL normal saline (Control)
Number of subjects: 54
Study 33751203 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Number of subjects: 54
Study 34301498 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy (EQD2 dose to 90% of High Risk CTV)
Number of subjects: 48
Study 34301498 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy (complications)
Number of subjects: 48
Study 34301498 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy (rectal dose correlation)
Number of subjects: 48
Study 34301498 — intervention group
Group type: COMPARATOR
Intervention: Brachytherapy (comparison with STIC PDR group)
Number of subjects: 48
Study 34301498 — intervention group
Group type: COMPARATOR
Intervention: Brachytherapy (comparison with retroEMBRACE cohort)
Number of subjects: 48
Study 34301498 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy (training and referral)
Number of subjects: 48
Study 32272901 — intervention group
Group type: EXPERIMENTAL
Intervention: UrApp-supported care
Number of subjects: 60
Study 32272901 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 60
Study 34997522 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation intervention (print-based materials provided once a week for 7 weeks)
Number of subjects: 393
Study 34997522 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (materials provided after the second survey)
Number of subjects: 393
Study 33259910 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneipp arm affusions
Number of subjects: 30
Study 33259910 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 30
Study 32621729 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 42
Study 32621729 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic Training (AT)
Number of subjects: 42
Study 32621729 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 42
Study 35094483 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld iontophoresis device
Number of subjects: 24
Study 32040781 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal therapy for localized prostate cancer
Number of subjects: 0
Study 32040781 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy (MRI-TRUS fusion image-guided biopsy)
Number of subjects: 0
Study 32040781 — intervention group
Group type: COMPARATOR
Intervention: TRUS-guided systematic biopsy
Number of subjects: 0